{"id":"W4389480868","doi":"10.1016/j.iotech.2023.100606","title":"134P A phase I study exploring the safety and tolerability of the small molecule PD-L1 inhibitor INCB099318 in select advanced solid tumors","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Chugai Pharmaceutical; Incyte; Sierra Oncology; Da Volterra; Ipsen; Eisai; Bristol-Myers Squibb; AstraZeneca; Carrick Therapeutics; Pfizer; Dr. Falk Pharma; ViiV Healthcare","keywords":"Tolerability; Medicine; Pharmacokinetics; Internal medicine; Adverse effect; Clinical endpoint; Gastroenterology; Oncology; Pharmacology; Clinical trial","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006272413,0.0004082361,0.0005784148,0.0002503366,0.0002435471,0.000418423,0.0003570127,0.000406785,0.008786066],"category_scores_gemma":[0.0006203933,0.0001326791,0.0007070694,0.0003212448,0.0001979104,0.0002500825,0.0001994739,0.00151195,0.001363833],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005537936,"about_ca_system_score_gemma":0.0009629517,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001248436,"about_ca_topic_score_gemma":0.002594083,"domain_scores_codex":[0.9998196,0.00007009254,0.00001011373,0.00002851872,0.00004118709,0.00003052369],"domain_scores_gemma":[0.9997085,0.00007501457,0.00005086889,0.0000226128,0.00004576483,0.00009722596],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2135749,0.02833087,0.02167068,0.001738236,0.001718266,0.0009731019,0.0001350057,0.004382869,0.1334693,0.0009534284,0.07848437,0.514569],"study_design_scores_gemma":[0.2414443,0.4958096,0.1070449,0.0001997891,0.001598189,0.003049563,0.0001039547,0.004920234,0.05225696,0.001142077,0.09233873,0.00009160762],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9301314,0.003341478,0.004019354,0.002016396,0.0002203121,0.005933326,0.03418713,0.0004515289,0.01969898],"genre_scores_gemma":[0.9247515,0.00356502,0.007263955,0.00236296,0.0001563601,0.004462042,0.04215483,0.0001185568,0.01516485],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008786066,"threshold_uncertainty_score":0.0293923,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04229348806635307,"score_gpt":0.3719076108827646,"score_spread":0.3296141228164115,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}